↓ Skip to main content

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

Overview of attention for article published in Frontiers in Pharmacology, January 2024
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
4 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
Published in
Frontiers in Pharmacology, January 2024
DOI 10.3389/fphar.2024.1269922
Pubmed ID
Authors

Dongqing Pu, Yue Wu, Debo Xu, Guangxi Shi, Hanhan Chen, Dandan Feng, Mengdi Zhang, Jingwei Li

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 25%
Unknown 3 75%
Readers by discipline Count As %
Unspecified 1 25%
Unknown 3 75%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#15,655,267
of 25,260,058 outputs
Outputs from Frontiers in Pharmacology
#5,275
of 19,472 outputs
Outputs of similar age
#91,963
of 216,188 outputs
Outputs of similar age from Frontiers in Pharmacology
#39
of 421 outputs
Altmetric has tracked 25,260,058 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,472 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 216,188 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 421 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.